Loading
Life sciences · Journal article
Biomedicines · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Epithelial-derived carcinomas exhibit genomic instability due to genetic mutation and epigenetic dysregulation. Mechanisms such as DNA methylation, histone modifications, and noncoding RNA regulation may lead to tumor progression, immune evasion, and treatment resistance. Presently, gene-based and epigenetic therapies, including CRISPR systems, RNA interference, and chromatin-modifying agents, are reported to be effective in targeted cancer treatment. Objectives: This scoping review aims to map the evidence on gene-based technologies in epithelial-derived carcinomas, including therapeutic, diagnostic, prognostic, screening, and disease-modeling applications, and to identify molecular targets, translational outcomes, and gaps in the current evidence base. The review will characterize the molecular targets, gene-based approaches, cancer types, translational applications, and reported outcomes to identify evidence gaps, translational challenges, and priorities for future research. Methods: The scoping review was conducted as per PRISMA-ScR by conducting a literature search in databases such as PubMed, Embase, and Google Scholar, covering studies published between 2016 and 2026. In the inclusion criteria, all studies and reviews related to investigating gene-based, RNA-mediated, and epigenetic therapies in epithelial cancers were included. Thirty-six studies met the eligibility criteria. Results: Amongst the studies reviewed, the most common epithelial cancers reported were hepatocellular carcinoma, ovarian carcinoma, lung carcinoma, and pancreatic ductal adenocarcinoma. Among the epithelial-derived carcinomas identified in this review, HCC was the most frequently represented cancer; epigenetic alterations and therapies used were RNA-based therapies, CRISPR diagnostics, and epigenetic drugs. Ovarian and breast cancers targeting BRCA pathways and chromatin remodeling produced clinical translation outcomes. Lung and colorectal cancers showed moderate epigenetic involvement, often managed through combined therapeutic strategies. Pancreatic cancer therapies were limited by challenges in drug delivery despite identifiable molecular targets. Gene therapies such as CRISPR-based gene editing, RNAi/siRNA therapies, miRNA/lncRNA targeting, and HDAC inhibition were commonly reported. Conclusions: The present study indicates that the majority of epithelial-derived carcinomas can benefit from gene-based and epigenetic therapies. Though the majority of carcinomas, such as hepatocellular, have good clinical outcomes, pancreatic cancer has limited clinical translation.